IDEXX Laboratories (NASDAQ:IDXX) is witnessing an interesting time with
earnings per share growth. There have been transactions by financial management entities on the company's stocks, including both buying and selling.
Park Avenue Securities LLC sold 245 shares while
Meyer Handelman Co made new investments of around $2.16 million. Despite this, IDXX's stock performance underperformed on certain days, compared to competitors. The medical stocks seem to lag, raising questions about the right time to buy shares. Yet, firms like
GAMMA Investing LLC, Wedmont Private Capital, and First Hawaiian Bank have increased their holdings while some insiders raise questions due to stock disposals. Despite facing macroeconomic woes and forex headwinds, IDXX remains an attractive option to investors owing to its robust
financial fundamentals and the ability to capitalize effectively. Lowered revenue forecast for 2024 resulted from lagging vet visits and a strong dollar. However, the aging pet population is considered a solid long-term tailwind for the business. IDXX advanced the
Catalyst Platform's test menu to aid veterinarians in diagnosing pancreatitis internationally, reflecting another reason for its increased stock performance. Yet, the recent stock performance doesn't reveal the whole picture of its financial health. IDXX outperformed other medical stocks in terms of year-to-date changes.
Idexx Laboratories IDXX News Analytics from Fri, 15 Sep 2023 07:00:00 GMT to Sun, 23 Jun 2024 17:52:01 GMT -
